GnRH Agonist and hCG (Dual Trigger) Versus hCG Trigger for Final Oocyte Maturation in Expected Normal Responders With a High Immature Oocyte Rate: Study Protocol for a Randomized, Superiority, Parallel Group, Controlled Trial

What Was Tested

This clinical study looks at hCG (human chorionic gonadotropin).

The choice of trigger drug for the controlled ovarian hyperstimulation (COH) protocol correlates with the outcome of in vitro fertilization/intracytoplasmic sperm injection embryo transfer (IVF/ICSI-ET).

The co-administration of gonadotropin releasing hormone agonist (GnRH-a) and human chorionic gonadotropin (hCG), i.e., dual trigger, for final oocyte maturation, has received much attention in recent years.

Who Took Part

The abstract describes 90 individuals taking part.

PubMed tags the participants as women only.

How the Study Was Run

In design terms this was a randomized study.

Because people in this hCG (human chorionic gonadotropin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The researchers propose a study at the Affiliated Hospital of Shandong University of Chinese Medicine.

A total of 90 individuals undergoing COH use a fixed GnRH antagonist protocol.

The primary outcome is metaphase-II (MII) oocytes rate.

Secondary outcomes are number of oocytes retrieved, fertilization rate, top-quality embryos rate, blastula formation rate, embryo implantation rate, clinical pregnancy rate, miscarriage rate, live birth rate, cumulative pregnancy/live birth rates, and ovarian hyperstimulation syndrome (OHSS) rate.

What Was Measured

The choice of trigger drug for the controlled ovarian hyperstimulation (COH) protocol correlates with the outcome of in vitro fertilization/intracytoplasmic sperm injection embryo transfer (IVF/ICSI-ET).

PubMed files the paper under topics including Chorionic Gonadotropin, Gonadotropin-Releasing Hormone, Oocytes, Ovarian Hyperstimulation Syndrome, Ovulation Induction, Randomized Controlled Trials as Topic and Recombinant Proteins.

The authors tagged it with the keywords dual trigger, gonadotropin releasing hormone agonist, human chorionic gonadotropin, in vitro fertilization/intracytoplasmic sperm injection and normal ovarian responder.

What This Means in Plain Language

The paper is a randomized study of hCG (human chorionic gonadotropin) in 90 individuals.

The publication is from 2022 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.